Pembrolizumab,Trastuzumab,Zolbetuximab,Nivolumab,Ipilimumab,Tislelizumab
Merck,Roche,astellas,BMS,Beigene,leap therapeutics
[]
"last year saw claudin18.2 emerge as a sought-after novel oncology target. now here come positive survival data in the first setting in which the most advanced anti-claudin18.2 antibody, $alpmy zolbetuximab, might be approved." $lptx 
We cannot direct the wind, but we can adjust the sails... Family Office. Founder Princeton Biomedical Consul. LLC.